Cancer Center Support (CORE) Grant
Jackson Laboratory, Bar Harbor ME
Investigators
Linked publications & trials
Abstract
The overall mission of The Jackson Laboratory Cancer Center (JAXCC) is to bring genomic solutions to cancer medicine. We continue to develop a culture of scientific discovery, excellence, transdisciplinary research, and collaboration to yield tangible benefits to cancer patients extending beyond the generation of new knowledge. Our basic research goal is to tackle the question of âGenetics and Genomics of Aging and Cancerâ, while our translational intent is to contribute new concepts, technologies, and clinical education initiatives originating from basic science to advance precision cancer medicine. The JAXCC has been supporting the basic research of its members as well as cancer researchers at large for over 40 years by focusing on genetic models of cancer. This history laid the groundwork for development of a precision genetics Program focused on therapeutic resistance and bringing novel solutions to overcome it. Building on our success, our Research Program is evolving to add the dimension of aging to further our efforts towards translating our basic cancer research discoveries for the benefit of cancer patients. The JAXCC has 37 Program members and 22 Affiliate members across our Centerâs two research campuses, contributing to a single highly integrated Program. Our research is supported by three interactive and complementary Shared Resources, which provide access to cutting-edge technologies and expertise. JAXCC members are experts in varied fields converging on the cancer problem by bringing novel approaches in a concerted, transdisciplinary manner. These approaches and expertise include strengths in complex genetics, functional genomics, cross-species integration, and the development of innovative animal, cellular, and computational models for studying aging and cancer. Our organizational structure allows us to support such an integrated strategy to achieve impactful contributions that ultimately lead to advances in precision cancer medicine.
View original record on NIH RePORTER →